<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511936</url>
  </required_header>
  <id_info>
    <org_study_id>ILS-AMD-101</org_study_id>
    <nct_id>NCT04511936</nct_id>
  </id_info>
  <brief_title>Microcurrent Stimulation for Dry Age-related Macular Degeneration</brief_title>
  <acronym>i-SIGHT</acronym>
  <official_title>Microcurrent Stimulation Therapy for Dry Age-related Macular Degeneration (i-SIGHT): a Multicenter, Randomized, Double-masked, Clinical Device Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>i-Lumen Scientific, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>i-Lumen Scientific, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of microcurrent stimulation therapy for patients with dry&#xD;
      age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-masked, randomized trial of microcurrent stimulation for the treatment&#xD;
      of patients affected with dry age-related macular degeneration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    COVID-related delays.&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best-corrected distance visual acuity (CDVA) at one month timepoint.</measure>
    <time_frame>1 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected distance visual acuity (CDVA) response rate at 1 month visit.</measure>
    <time_frame>1 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>i-Lumen AMD Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>i-Lumen AMD Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>i-Lumen AMD</intervention_name>
    <description>Microcurrent stimulator</description>
    <arm_group_label>i-Lumen AMD Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>i-Lumen AMD Sham</intervention_name>
    <description>Sham microcurrent stimulator</description>
    <arm_group_label>i-Lumen AMD Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria - Study Eye:&#xD;
&#xD;
          -  Dry AMD diagnosis.&#xD;
&#xD;
        Key Exclusion Criteria - Study Eye:&#xD;
&#xD;
          -  Wet AMD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Dry AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

